Traumatic Brain Injury - Pipeline Review, H1 2020

January 2020 | 414 pages | ID: T810F74600DEN
Global Markets Direct

Abstracts

Traumatic Brain Injury - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2020, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape.

Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 8, 2, 93 and 16 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 2 molecules, respectively.

Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System).
• The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Traumatic Brain Injury - Overview
Traumatic Brain Injury - Therapeutics Development
Traumatic Brain Injury - Therapeutics Assessment
Traumatic Brain Injury - Companies Involved in Therapeutics Development
Traumatic Brain Injury - Drug Profiles
Traumatic Brain Injury - Dormant Projects
Traumatic Brain Injury - Discontinued Products
Traumatic Brain Injury - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Traumatic Brain Injury, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Traumatic Brain Injury - Pipeline by Acelerox LLC, H1 2020
Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2020
Traumatic Brain Injury - Pipeline by AlzeCure Pharma AB, H1 2020
Traumatic Brain Injury - Pipeline by AMAG Pharmaceuticals Inc, H1 2020
Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2020
Traumatic Brain Injury - Pipeline by American CryoStem Corp, H1 2020
Traumatic Brain Injury - Pipeline by Anagin Inc, H1 2020
Traumatic Brain Injury - Pipeline by Anida Pharma Inc, H1 2020
Traumatic Brain Injury - Pipeline by Annovis Bio Inc, H1 2020
Traumatic Brain Injury - Dormant Projects, H1 2020
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..1), H1 2020
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..2), H1 2020
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..3), H1 2020
Traumatic Brain Injury - Dormant Projects, H1 2020 (Contd..4), H1 2020
Traumatic Brain Injury - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Traumatic Brain Injury, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Acelerox LLC
ALSP Inc
AlzeCure Pharma AB
AMAG Pharmaceuticals Inc
Amarantus Bioscience Holdings Inc
American CryoStem Corp
Anagin Inc
Anida Pharma Inc
Annovis Bio Inc
AntiRadical Therapeutics LLC
Anvyl LLC
Aptinyx Inc
Astrocyte Pharmaceuticals Inc
Athersys Inc
Avanir Pharmaceuticals Inc
Bessor Pharma LLC
Beyond Barriers Therapeutics Inc
Biogen Inc
BioIncept LLC
Bioquark Inc
Brain-Gen LLC
CalciMedica Inc
CavoGene LifeSciences
CellCure
Cellvation Inc
CereSpir Inc
Chimerix Inc
Chrysalis BioTherapeutics Inc
Cognosci Inc
Complement Pharma BV
Deha Pharmaceutical LLC
Eagle Pharmaceuticals Inc
Eisai Co Ltd
Epigen Biosciences Inc
Fortuna Fix Inc
GABA Therapeutics Inc
GNT Pharma Co Ltd
Hemarina SA
Hibernaid Inc
Hillhurst Biopharmaceuticals Inc
Hope Biosciences LLC
Hoverink Biotechnologies Inc
ImmunoChem Therapeutics LLC
Impression Healthcare Ltd
Inflammatory Response Research Inc
International Stem Cell Corp
Ischemix Inc
JT Pharmaceuticals Inc
Kalytera Therapeutics Inc
KannaLife Sciences Inc
LA Cell Inc
Levolta Pharmaceuticals Inc
Mapreg SAS
Mercaptor Discoveries Inc
MetVital Inc
NeuExcell Therapeutics Inc
NeurAegis Inc
Neuren Pharmaceuticals Ltd
NeurExo Sciences LLC
Neurodon LLC
Neuronasal LLC
NeuroNascent Inc
NeuroTrauma Sciences LLC
Neurotrope Bioscience Inc
NeuroVive Pharmaceutical AB
New World Laboratories Inc
NoNO Inc
NuvOx Pharma LLC
Nyrada Inc
OncoSynergy Inc
Orpheris Inc
Oxeia Biopharmaceuticals Inc
Peptron Inc
PharmatrophiX Inc
Praetego Inc
Prevacus Inc
ProNeurogen Inc
ProThera Biologics Inc
Protheragen Inc
Qrons Inc
Radikal Therapeutics Inc
RegeneRx Biopharmaceuticals Inc
Resolys Bio Inc
RHNanopharmacuticals LLC
Rubicon Biotechnology Inc
SanBio Inc
Seneca Biopharma Inc
Shinkei Therapeutics LLC
Silver Creek Pharmaceuticals Inc
Spinogenix Inc
STATegics Inc
Stemedica Cell Technologies Inc
Swedish Orphan Biovitrum AB
Tellus Therapeutics Inc
Tetra Therapeutics
Thera Neuropharma Inc
Therapeutic Solutions International Inc
Therapix Biosciences Ltd
Theratome Bio Inc
TikoMed AB
Tiziana Life Sciences Plc
Tria Bioscience Corp
vasopharm GmbH
VG Life Sciences Inc
Virogenomics BioDevelopment Inc
Xcelthera INC
Xonovo Inc
ZyVersa Therapeutics Inc